Literature DB >> 17351543

[Can myelopathies secondary to arterio-venous dural fistulae be aggravated by intravenous corticosteroid therapy?].

M E Söderlund1, S Benisty, A Gaston, M Djindjian, P Cesaro, A Créange.   

Abstract

Dural fistulas are the most common vascular malformations of the spinal cord. They are of unknown origin but constitute a recognized cause of myelopathy. Aggravation of the clinical manifestations, either spontaneously or after invasive procedures, has been described. We report the case of a patient with a four-month history of myelopathic syndrome involving the lower limbs. Intravenous corticosteroid steroid treatment (1g) given for a suspected inflammatory disorder, induced a dramatic flare-up of the neurological symptoms which were reversible within 48 hours after corticosteroid withdrawal. The causal effect of the steroid treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351543     DOI: 10.1016/s0035-3787(07)90395-1

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Reversible aggravation of neurological deficits after steroid medication in patients with venous congestive myelopathy caused by spinal arteriovenous malformation.

Authors:  C-S Lee; H W Pyun; E Y Chae; K-K Kim; S C Rhim; D C Suh
Journal:  Interv Neuroradiol       Date:  2009-11-04       Impact factor: 1.610

2.  Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of longitudinally extensive transverse myelitis caused by spinal dural arteriovenous fistula: case report and review of literature.

Authors:  Michael A DiSano; Russell Cerejo; MaryAnn Mays
Journal:  Spinal Cord Ser Cases       Date:  2017-05-18

3.  Factors Associated with Rapidly Deteriorating Myelopathy in Patients with Spinal Arteriovenous Shunts.

Authors:  Takahiro Miyahara; Gohsuke Hattori; Hisaaki Uchikado; Yasuyuki Kaku; Yuki Ohmori; Kimihiko Orito; Yasuharu Takeuchi; Takayuki Kawano; Masaru Hirohata; Akitake Mukasa; Motohiro Morioka
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-11-12       Impact factor: 1.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.